Hilda A. de Barros

Hilda A. de Barros

Auto-generated profile, based on publicly available information

Hilda A. de Barros

Department of Urology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SLSimon Linder
Simon Linder
MHMarlous Hoogstraat
Marlous Hoogstraat
SSSuzan Stelloo
Suzan Stelloo
NENils Eickhoff
Nils Eickhoff
KSKarianne Schuurman
Karianne Schuurman
WZWilbert Zwart
Wilbert Zwart
In prostate cancer, androgen receptor (AR)–targeting agents are very effective in various disease stages. However, therapy resistance inevitably occurs, and little is known about how tumor cells adapt to bypass AR suppression. Here, we performed integrative multiomics analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide monotherapy from patients with high-risk prostate cancer enrolled in a neoadjuvant clinical trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors toward a neuroendocrine-like disease state. Additionally, epigenomic profiling revealed massive enzalutamide-induced reprogramming of pioneer factor FOXA1 from inactive chromatin sites toward active cis-regulatory elements that dictate prosurvival signals. Notably, treatment-induced FOXA1 sites were enriched for the circadian clock component ARNTL. Posttreatment ARNTL levels were associated with patients’ clinical outcomes, and ARNTL knockout strongly decreased prostate cancer cell growth. Our data highlight a remarkable cistromic plasticity of FOXA1 following AR-targeted therapy and revealed an acquired dependency on the circadian regulator ARNTL, a novel candidate therapeutic target. Significance: Understanding how prostate cancers adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenomic plasticity toward prosurvival signaling and uncovered the circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel lead for therapeutic development. See related commentary by Zhang et al., p. 2017. This article is highlighted in the In This Issue feature, p. 2007

23 March 2022 in European Urology
Verified
Journal Article
Closed access
HBHilda A. de Barros
Hilda A. de Barros
MOMatthias N. van Oosterom
Matthias N. van Oosterom
MDMaarten L. Donswijk
Maarten L. Donswijk
JHJeroen J.M.A. Hendrikx
Jeroen J.M.A. Hendrikx
AVAndré N. Vis
André N. Vis
PLPim J. van Leeuwen
Pim J. van Leeuwen

29 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LZLotte Guusta Zuur
Lotte Guusta Zuur
HBHilda A. de Barros
Hilda A. de Barros
JMJohannes Van der Mijn
Johannes Van der Mijn
AVAndré Vis
André Vis
ABAndries Bergman
Andries Bergman
PLPim J. Van Leeuwen
Pim J. Van Leeuwen
There is currently no consensus on the optimal treatment for patients with a primary diagnosis of clinically and pathologically node-positive (cN1M0 and pN1M0) hormone-sensitive prostate cancer (PCa). The treatment paradigm has shifted as research has shown that these patients could benefit from intensified treatment and are potentially curable. This scoping review provides an overview of available treatments for men with primary-diagnosed cN1M0 and pN1M0 PCa. A search was conducted on Medline for studies published between 2002 and 2022 that reported on treatment and outcomes among patients with cN1M0 and pN1M0 PCa. In total, twenty-seven eligible articles were included in this analysis: six randomised controlled trials, one systematic review, and twenty retrospective/observational studies. For cN1M0 PCa patients, the best-established treatment option is a combination of androgen deprivation therapy (ADT) and external beam radiotherapy (EBRT) applied to both the prostate and lymph nodes. Based on most recent studies, treatment intensification can be beneficial, but more randomised studies are needed. For pN1M0 PCa patients, adjuvant or early salvage treatments based on risk stratification determined by factors such as Gleason score, tumour stage, number of positive lymph nodes, and surgical margins appear to be the best-established treatment options. These treatments include close monitoring and adjuvant treatment with ADT and/or EBRT.

10 November 2022 in European Urology Oncology
Verified
Journal Article
Closed access
HBHilda A. de Barros
Hilda A. de Barros
IBIsabeau van Beurden
Isabeau van Beurden
MDMatteo Droghetti
Matteo Droghetti
EWErica A. Wilthagen
Erica A. Wilthagen
OÖOktay Özman
Oktay Özman
HPHenk G. van der Poel
Henk G. van der Poel

12 February 2024 in BJU International
Verified
Journal Article
Closed access
LZLotte Guusta Zuur
Lotte Guusta Zuur
HBHilda A. de Barros
Hilda A. de Barros
MOMatthias N. van Oosterom
Matthias N. van Oosterom
ABAnne‐Claire Berrens
Anne‐Claire Berrens
MDMaarten L. Donswijk
Maarten L. Donswijk
PLPim J. van Leeuwen
Pim J. van Leeuwen

6 July 2023 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JDJan J. Duin
Jan J. Duin
HBHilda A. de Barros
Hilda A. de Barros
MDMaarten L. Donswijk
Maarten L. Donswijk
ESEva E. Schaake
Eva E. Schaake
TSTim M. van der Sluis
Tim M. van der Sluis
HPHenk G. van der Poel
Henk G. van der Poel
Our objective was to assess the diagnostic value of the sentinel node (SN) procedure for lymph node staging in primary intermediate- and high-risk prostate cancer patients with node-negative results on prostate-specific membrane antigen PET/CT (miN0). Methods: From 2016 to 2022, 154 patients with primary, miN0 PCa were retrospectively included. All patients had a Briganti nomogram–assessed nodal risk of more than 5% and underwent a robot-assisted SN procedure for nodal staging. The prevalence of nodal metastases at histopathology and the occurrence of surgical complications according to the Clavien–Dindo classification were evaluated. Results: The SN procedure yielded 84 (14%) tumor-positive lymph nodes with a median metastasis size of 3 mm (interquartile range, 1–4 mm). In total, 55 patients (36%) were reclassified as pN1. A complication of Clavien–Dindo grade 3 or higher occured in 1 patient (0.6%). Conclusion: The SN procedure classified 36% of patients with miN0 prostate cancer with an elevated risk of nodal metastases as pN1.